R&D | October 29, 2025
Medherant’s testosterone TEPI Patch could become the first-in-class testosterone patch developed specifically for women
The new CMC Process R&D Center represents a strategic investment in scale, sustainability, and specialization
Partnership combines MilliporeSigma’s chemistry and organoid expertise with Promega’s assay technologies
It will produce a comprehensive range of dosage forms including tablets, hard gelatin capsules, liquids, injectables, topicals, and beta-lactam products
Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose
In the next five years, an additional 75,000 seats are expected to be added across both undergraduate and postgraduate levels
The event will be attended by 35,000+ industry professionals
The acquisition will follow the planned separation of Avidity’s early-stage precision cardiology programs into a new, independent company
Agreement adds a new preclinical ADC with potential for enhanced anti-tumour activity and best-in-class profile
Subscribe To Our Newsletter & Stay Updated
